In humans there appears tobe a relationship of myostatin genetic polymorphisms andpeak BMD, suggesting that different levels of myostatin expression might be correlated with higher (or lower) BMD[72]. In the ACE-031 trial described above, a significant increase in bone specific alkaline phosphatase and significant decrease in C-telopeptide compared with placebo was ob-served [55•]. This could suggest an uncoupling of bone re-modeling. Unfortunately, BMD data were not reported [55•].In the previously noted phase 1b trial BMD data have beenreported on the company’s website. At a higher dosing regi-men of 2 mg every 4 weeks for a total of 2 doses a significantincrease of 3.4 % was found after 113 days. Bone specificalkaline phosphatase increased and CTX decreased in thisstudy as well, similar to the published findings